Savara, a clinical stage biopharmaceutical company focused on rare respiratory diseases, entered into a term loan agreement of $26.5 million with Silicon Valley Bank to replace its existing credit facility with the bank.
Click Therapeutics secured a $15 million term loan from Silicon Valley Bank and used proceeds from the financing in part to retire its existing term loan facility with K2 HealthVentures.
iRhythm Technologies, a digital healthcare solutions company focused on the advancement of cardiac care, amended its existing debt facility with Silicon Valley Bank. The agreement improves upon the pricing and terms of iRhythm’s existing credit facility.
EyePoint Pharmaceuticals entered into a loan agreement providing for senior secured credit facilities in the aggregate amount of $45 million with Silicon Valley Bank to replace its existing credit facility with CRG Servicing.
Progress, a provider of products to develop, deploy and manage high-impact applications, entered into an amended secured credit facility in the aggregate amount of $575 million. JPMorgan Chase Bank acted as administrative agent for the transaction.
Silicon Valley Bank provided a debt facility to Liquidia that provides up to $40 million in term loans, of which $20 million was funded at closing.
Veeco Instruments entered into a senior secured revolving credit facility that enables the company to borrow up to $150 million over a five-year term that expires in December 2026. HSBC Bank is acting as administrative agent and collateral agent for the facility.
SmartRent entered into a $75 million senior secured revolving credit facility with a five-year term. Silicon Valley Bank, serving as lead arranger and administrative agent, and J.P. Morgan provided the facility.
SVB Financial Group expanded its technology investment banking team with additional hires in the internet, consumer/marketing software, fintech and enterprise software sectors and the launch of technology leveraged finance and equity capital markets capabilities.
Viracta Therapeutics, a precision oncology company primarily focused on targeting virus-associated malignancies, entered into a loan and security agreement with Silicon Valley Bank and Oxford Finance for up to $50 million.